13F Holdings
中文EN

VSBC VITASPRING BIOMEDICAL CO. LTD.

Services-Commercial Physical & Biological Research · OTC · SEC CIK 1697884 · Fiscal year ends 01/31

Financial factors as of 2026-07-31 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY14.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,861.9%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets31,554.8%
Debt / equity—
Current ratio0.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.02x
Accruals ratio-2,928.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-01-31FY20252025-01-31FY20242024-01-31FY20232023-01-31FY20212022-01-31
Income statement
Revenue$0$0$0$0$5.61M
Cost of revenue$0$0$0$3.33M$3.55M
Gross profit$0$0$0-$3.33M$2.07M
SG&A expense$385,411$679,914$1.12M$844,836$941,336
Operating income-$385,411-$679,914-$1.12M-$4.18M$1.13M
Pretax income-$385,411-$679,914-$1.12M-$4.17M$1.13M
Income tax$29,957$95,008$0-$5,381$217,104
Net income-$415,368-$774,922-$1.12M-$4.16M$909,560
EBITDA-$375,454-$669,957-$1.10M-$4.16M$1.14M
EPS (diluted)0.000.00-0.01-0.020.00
Weighted avg. shares (diluted)207.03M207.03M207.03M206.52M205.98M
Balance sheet
Cash & equivalents$2,084$272$13$29,656$107,212
Receivables—$0$0$380,000$2.95M
Inventory———$0$0
Current assets$10,527$272$23,627$437,078$3.06M
PP&E, net$4,149$14,106$24,063$49,574$64,636
Total assets$14,676$14,378$137,342$765,948$3.60M
Current liabilities$4.45M$4.03M$3.49M$3.07M$1.74M
Total liabilities$4.45M$4.03M$3.49M$3.16M$2.03M
Shareholders' equity-$4.43M-$4.02M-$3.35M-$2.40M$1.58M
Shares outstanding207.03M207.03M—152.08M118.59M
Cash flow statement
Operating cash flow-$2,688-$14,675-$34,920-$77,556-$269,631
Capital expenditure———$0$72,997
Free cash flow———-$77,556-$342,628
Investing cash flow———$0-$72,997
Financing cash flow$4,500$14,934$5,277$0$50,000
Depreciation & amortization$9,957$9,957$15,062$15,062$8,361
Stock-based compensation$0$109,911$164,865$190,365$167,173

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.